ACERIL – CAPTOPRIL
 |
|
|
Package(a):
TABLETS: 90 x 12.5 mg.
Dosage(a):
Hypertension: 25-50 mg daily in 2 divided doses. The dose may be increased incrementally, with intervals of at least 2 weeks, to 100-150 mg daily in 2 divided doses as needed, to reach target blood pressure.
CHF: Usual starting dose: 6.25-25 mg BID or TID. Titration to the maintenance dose (75-150 mg daily) should be carried out based on patient's response, clinical status and tolerability up to a maximum of 150 mg daily in divided doses. The dose should be increased incrimentally, with intervals of at least 2 weeks to evaluate patient's response.
Type I diabetic nephropathy: 75-100 mg in divided doses.
MI, renal impairment, children and adolescents: See literature.
Prescribing Restrictions: None
Package(b):
TABLETS: 90 x 25 mg.
Dosage(b):
Hypertension: 25-50 mg daily in 2 divided doses. The dose may be increased incrementally, with intervals of at least 2 weeks, to 100-150 mg daily in 2 divided doses as needed, to reach target blood pressure.
CHF: Usual starting dose: 6.25-25 mg BID or TID. Titration to the maintenance dose (75-150 mg daily) should be carried out based on patient's response, clinical status and tolerability up to a maximum of 150 mg daily in divided doses. The dose should be increased incrimentally, with intervals of at least 2 weeks to evaluate patient's response.
Type I diabetic nephropathy: 75-100 mg in divided doses.
MI, renal impairment, children and adolescents: See literature.
Prescribing Restrictions: None
Package(c):
TABLETS: 90 x 50 mg.
Dosage(c):
Hypertension: 25-50 mg daily in 2 divided doses. The dose may be increased incrementally, with intervals of at least 2 weeks, to 100-150 mg daily in 2 divided doses as needed, to reach target blood pressure.
CHF: Usual starting dose: 6.25-25 mg BID or TID. Titration to the maintenance dose (75-150 mg daily) should be carried out based on patient's response, clinical status and tolerability up to a maximum of 150 mg daily in divided doses. The dose should be increased incrimentally, with intervals of at least 2 weeks to evaluate patient's response.
Type I diabetic nephropathy: 75-100 mg in divided doses.
MI, renal impairment, children and adolescents: See literature.
Prescribing Restrictions: None
Indications:
Hypertension, C.H.F., insulin dependent diabetic nephropathy in hypertensive and non-hypertensive patients in cases where the serum creatinine level <2.5 mg/dl. Left ventricular dysfunction after MI. To improve survival following MI in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction < or equals to 40% and to reduce the incidence of overt heart failure and subsequent hospitalization for CHF in these patients.
Contra-Indications:
Pregnancy and breastfeeding. Hypersensitivity to one of the ingredients or other ACE inhibitors. Previous reaction which included swelling of the hands, face, lips or tongue of unknown origin. See literature.
Special Precautions:
Angioedema, anaphylactoid reactions, neutropenia/agranulocytosis, proteinuria, hypotension, impaired renal function, hyperkalemia, major surgery, anesthesia. See literature.
Side Effects:
Proteinuria, elevated blood urea and creatinine, elevated serum potassium and acidosis, renal insufficiency, rash, pruritus, flushing or pallor, hypotension, tachycardia, chest pain and palpitations, dysgeusia, stomatitis, resembling aphthous ulcers, cough. See literature.
Drug Interactions:
Alcohol, allopurinol, NSAIDs, antidepressants, antidiabetics, cyclosporin, diuretics, lithium, nitrates, estrogens and progesterones, potassium salts, carbenoxolone, indomethacin, minoxidil, vasodilators, procainamide, azathioprine, cyclophosphamide, probenecid, digoxin. See literature.
